Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

485
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
485
Accessory Glands of the Male Reproductive System01:16

Accessory Glands of the Male Reproductive System

1.8K
The accessory ducts involved in sperm maturation and transportation include the epididymides, vasa deferentia, ejaculatory ducts, and urethra. These ducts play a critical role in the maturation, storage, and transportation of sperm from the testes to the urethra, where it is then released during ejaculation.
The epididymis is a small, comma-shaped organ located at the back of each testicle. The epididymis can be divided into three main parts: the head, body, and tail. The head of the epididymis...
1.8K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

228
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
228
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

200
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
200
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

241
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
241
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

893
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
893

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Practical management of hematuria after endoscopic surgery for benign prostatic obstruction.

Prostate cancer and prostatic diseases·2026
Same author

Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes.

Prostate cancer and prostatic diseases·2026
Same author

Modern day cost analysis demonstrates medical therapy as a highly cost‑effective first‑line treatment for BPH/LUTS.

Prostate cancer and prostatic diseases·2026
Same author

12-Month Outcomes From a Randomized, Sham-Controlled Trial Evaluating a Novel Prostatic Urethral Stent for the Treatment of Benign Prostatic Hyperplasia.

The Journal of urology·2025
Same author

Extended LUTS medication use following BPH surgical treatment: a US healthcare claims analysis.

Prostate cancer and prostatic diseases·2025
Same author

Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study).

Prostate cancer and prostatic diseases·2024
Same journal

Urinary Supersaturation in a Randomized Trial among Individuals with Recurrent Nephrolithiasis comparing Empiric versus Selective Preventive Therapy: The URINE Trial.

The Journal of urology·2026
Same journal

Phentermine/Topiramate in Obese, Diabetic Uric Acid Stone Formers: An Open-Label Randomized Feasibility Trial.

The Journal of urology·2026
Same journal

Oncological Outcomes of Non-Muscle Invasive Bladder Cancer in Patients Aged ≤45: A Retrospective Matched Cohort Study.

The Journal of urology·2026
Same journal

The Effect of Prostate Volume and 5-Alpha Reductase Inhibitor Use on Grade Progression and Treatment Decisions in Patients with Prostate Cancer on Active Surveillance.

The Journal of urology·2026
Same journal

Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guérin (BCG)‒Naïve Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes.

The Journal of urology·2026
See all related articles

Related Experiment Video

Updated: Jul 31, 2025

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.1K

Benign Prostatic Hyperplasia

Steven A Kaplan

    The Journal of Urology
    |May 9, 2023
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
    05:25

    Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

    Published on: August 14, 2019

    19.3K
    Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
    05:28

    Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

    Published on: May 5, 2020

    2.3K

    Related Experiment Videos

    Last Updated: Jul 31, 2025

    Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
    06:04

    Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

    Published on: March 6, 2018

    17.1K
    Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
    05:25

    Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

    Published on: August 14, 2019

    19.3K
    Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
    05:28

    Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

    Published on: May 5, 2020

    2.3K